Best Response to PDE5 Inhibitors in Organic Erectile Dysfunction

Effectiveness of PDE5 Inhibitors Across Different Populations

Men with erectile dysfunction in the general population respond best to PDE5 inhibitors, while those with diabetes and post-prostatectomy patients have more severe ED at baseline and respond less robustly to these medications 1
PDE5 inhibitors have similar efficacy in the general ED population, with high-quality evidence showing significant improvement in erectile function compared to placebo 1, 2
The weighted mean percentage of successful sexual intercourse attempts is approximately 69% for sildenafil, 68% for vardenafil, and 69% for tadalafil versus only 33-36% for placebo in the general ED population 2, 3

Proper medication use significantly impacts treatment success, with incorrect use accounting for a large percentage of treatment failures 1, 5
Dose titration is essential for optimal efficacy, with higher doses of sildenafil and vardenafil showing improved erectile function 2, 4
In men with mild to moderate hepatic or renal impairment or spinal cord injury, PDE5 inhibitors should be used with caution at lower initial doses due to potential delayed metabolism 1, 6

Men with specific medical conditions such as diabetes, depression, cardiovascular disease, prostate cancer, multiple sclerosis, colorectal cancer, schizophrenia, liver failure, and renal failure can experience improved erections with PDE5 inhibitors, though response rates vary 2, 3
Post-prostatectomy patients respond less robustly to PDE5 inhibitors but still show benefit with on-demand use during treatment 1, 4

Patient education is crucial, particularly explaining that sexual stimulation is necessary and that more than one trial with the medication may be required to establish efficacy 1, 5
Dose titration should be performed to balance efficacy against adverse events, finding the optimal dose that meets treatment expectations without unacceptable side effects 1, 4

The most frequently reported adverse events with PDE5 inhibitors are dyspepsia, headache, flushing, back pain, nasal congestion, myalgia, visual disturbance, and dizziness 1, 7
Concurrent use of nitrates in any form is a contraindication for oral PDE5 inhibitor therapy due to risk of severe hypotension 7, 6

Begin with the standard recommended starting dose of the chosen PDE5 inhibitor for patients in the general ED population 1, 2
For patients with diabetes or post-prostatectomy ED, consider starting at the higher end of the dosing range, as these populations typically require higher doses for efficacy 1, 4
Provide clear instructions on proper medication use, emphasizing the need for sexual stimulation and potential need for multiple trials 1, 5
If initial treatment is unsuccessful, consider dose adjustment before concluding treatment failure 1, 4